Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D Hypoxia-Preconditioned UC-MSCs in Haploidentical HSCT for Severe Aplastic Anemia
NCT07299123Phase 2Enrolling by invitation
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in aplastic anemia (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Adverse Events at 150 days. Started Aug 2022; status: enrolling by invitation.
02
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07299123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299123.